PCSK9 and acute myocardial infarction: Recently published PACMAN-AMI (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction) randomized trial has shown that aggressive lipid-lowering leads to degeneration of plaque vulnerability features, including macrophage infiltration [21].